Last reviewed · How we verify
NCT04826159
IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2)
Phase 2 trial testing IMB-1018972 in Type 2 Diabetes in 49 participants. Completed in 6 August 2024.
6 August 2024
Quick facts
| Lead sponsor | Imbria Pharmaceuticals, Inc. |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 49 |
| Start date | 21 April 2021 |
| Primary completion | 6 August 2024 |
| Estimated completion | 6 August 2024 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- IMB-1018972 — full drug profile →
Conditions studied
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
- Diabetic Cardiomyopathies — all drugs for Diabetic Cardiomyopathies →
- HFpEF - Heart Failure With Preserved Ejection Fraction — all drugs for HFpEF - Heart Failure With Preserved Ejection Fraction →
Sponsor
Imbria Pharmaceuticals, Inc. — full company profile →
Who can join
Adults 18 to 80, any sex, with Type 2 Diabetes or Diabetic Cardiomyopathies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to assess the activity of IMB-1018972 on cardiac energetic reserve at rest and during stress and to assess safety and tolerability
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Diabetic cardiomyopathy: Early diagnostic biomarkers, pathogenetic mechanisms, and therapeutic interventions.
Huo JL, Feng Q, Pan S, Fu WJ, et al · · 2023 · cited 83× · PMID 37479697 · DOI 10.1038/s41420-023-01553-4 -
Myocardial Metabolism in Heart Failure with Preserved Ejection Fraction.
Henry JA, Couch LS, Rider OJ. · · 2024 · cited 17× · PMID 38592048 · DOI 10.3390/jcm13051195 -
Update on clinical and experimental management of diabetic cardiomyopathy: addressing current and future therapy.
Galis P, Bartosova L, Farkasova V, Bartekova M, et al · · 2024 · cited 8× · PMID 39140033 · DOI 10.3389/fendo.2024.1451100 -
IMPROVE-DiCE, a 2-Part, Open-Label, Phase 2a Trial Evaluating the Safety and Effectiveness of Ninerafaxstat in Patients With Cardiometabolic Syndromes.
Hundertmark MJ, Birkhoelzer SM, Portwood C, Siu AG, et al · · 2026 · cited 3× · PMID 41410037 · DOI 10.1161/circulationaha.125.074041 -
Modulating Cardiac Energetics in Cardio-Metabolic Syndromes: A mechanistic, hyperpolarized MR Trial of Ninerafaxstat Treatment
Hundertmark MJ, Siu AG, Matthews V, Lewis AJ, et al · · 2024 · cited 1× · DOI 10.1101/2024.04.24.591019 -
Current Treatment of Heart Failure with Preserved Ejection Fraction.
Riccardi M, D'Elia E, Lombardi CM, Savarese G, et al · · 2025 · PMID 40807027 · DOI 10.3390/jcm14155406
Verify or expand the search:
- PubMed search for NCT04826159
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of IMB-1018972
Trials testing the same drug.
- NCT04826185 — A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic · Phase 2 · completed
- NCT04826172 — Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstru · Phase 2 · completed
Other recruiting trials for Type 2 Diabetes
Currently open trials in the same condition.
- NCT07053319 — SGLT2i, Pioglitazone, and Ketone Production in T2D · Phase 1 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07463859 — Effects of Periodontal Treatment Associated With Antimicrobial Photodynamic Therapy on Halitosis in Patients With Diabet · NA · recruiting
- NCT07254689 — The Food for Health Study · NA · recruiting
- NCT07558863 — Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes · Phase 4 · recruiting
Other Imbria Pharmaceuticals, Inc. trials
Trials by the same sponsor.
- NCT04826185 — A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic · Phase 2 · completed
- NCT04826172 — Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstru · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04826159 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Imbria Pharmaceuticals, Inc.
- Last refreshed: 29 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04826159.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing